The BC genotype of the VNTR polymorphism of platelet glycoprotein Ibα is overrepresented in patients with recurrent stroke regardless of aspirin therapy

Background: The contribution of genetic factors to aspirin treatment failure (ATF) for secondary prevention is not settled in patients with ischemic stroke. Methods: We assessed the polymorphisms VNTR ( A, B, C, D) of glycoprotein ( GP) Ib alpha, 807C/T of GP Ia/IIa, and PIA1/A2 of GP IIb/IIIa, and the 5-year incidence of major recurrent events in 82 stroke patients with no major sources of cardioembolism ( mean age 70, SD 9.0 years; female gender 23%). Using a structured interview, all participants confirmed good compliance with aspirin (100-300 mg/day) for secondary prevention. Demographics and atherothrombotic risk factors assessed included diabetes, hypertension, dyslipemia, smoking, and coronary heart disease. Results: Thirty-one stroke patients had one recurrent stroke or myocardial infarction within 33 (7-48) months of aspirin onset, while 51 patients demonstrated an uneventful clinical course. Female gender (p < 0.05), diabetes (p < 0.05), dyslipemia (p < 0.05), and the BC genotype of VNTR (25.8 vs. 7.8%, p < 0.05) were more prevalent in patients in whom aspirin failed to prevent clinical events than in those in whom it did not. The BC genotype of VNTR was the only factor that remained associated with ATF in an age-, sex-, and risk factor-adjusted logistic regression analysis (OR 9.6, 95% CI 1.5-61.0). Conclusion: The BC genotype of the VNTR polymorphism of GP Ib alpha is an independent predictor of recurrent events in stroke patients treated with aspirin. This finding suggests that high shear-induced platelet activation mediated by GP Ib alpha and von Willebrand factor is an important contributor to ATF in the stroke population. Copyright (c) 2007 S. Karger AG, Basel.